Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tumor marker tests in bladder cancer].

G Feil1, A Stenzl

  • 1Departamento de Urología, Universidad Eberhard Karl, Tübingen, Alemania. gerhard.feil@med.uni-tuenbingen.de

Actas Urologicas Espanolas
|May 18, 2006
PubMed
Summary

Non-invasive bladder cancer tests show improved sensitivity over urine cytology but lack the high specificity needed to replace cystoscopy. Current markers are not ideal for replacing diagnostic procedures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Impact of sociodemographic and socioeconomic factors on functional and health-related quality of life outcomes 24 months after radical prostatectomy.

Journal of cancer research and clinical oncology·2025
Same author

Retrospective analysis of different application methods in intratympanic glucocorticoid therapy for treatment of idiopathic SSNHL: A comparative outcome study.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2025
Same author

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A high-fidelity prototype of a sterile information system for the perioperative area: OR-Pad.

International journal of computer assisted radiology and surgery·2022

Area of Science:

  • Urology
  • Oncology
  • Biomarker Development

Context:

  • Cystoscopy is the gold standard for bladder cancer detection but is invasive.
  • Urine cytology has high specificity but low sensitivity for early-stage tumors.
  • There is a need for non-invasive tests to improve bladder cancer detection and monitoring.

Purpose:

  • To evaluate the efficacy of FDA-approved non-invasive bladder tumor markers.
  • To compare the diagnostic performance of these markers against cystoscopy and urine cytology.
  • To determine if any non-invasive marker can replace cystoscopy in bladder cancer follow-up.

Summary:

  • Several FDA-approved non-invasive bladder tumor markers (ImmunoCyt/uCyt+, BTA TRAK, BTA stat, NMP22, NMP22 BladderChek, UroVysion) were investigated.
  • These tests demonstrated higher sensitivity than urine cytology, with mean sensitivities of 64-80% and specificities of 71-95%.
  • However, BTA TRAK, BTA stat, NMP22, and NMP22 BladderChek showed false positives with benign conditions; none achieved both high sensitivity and specificity to replace cystoscopy.

Impact:

  • Current non-invasive bladder cancer markers do not possess sufficient sensitivity and specificity to replace cystoscopy.
  • Further development is needed to create ideal tumor markers for bladder cancer diagnosis and management.
  • These findings highlight limitations in current non-invasive diagnostic tools for bladder cancer.

Related Experiment Videos